Alcon develops and markets surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products through Surgical and Vision Care segments, with the Surgical segment offering implantable products, consumables and equipment for cataracts, vitreoretinal conditions, refractive errors, and glaucoma, while the Vision Care segment comprises contact lenses and ocular health products. The company successfully launched a wave of innovative new products that fueled sales acceleration in 2025.
Cyborg Score Rationale
Alcon achieved 7% sales growth in 2025 with 2026 guidance calling for 5-7% sales growth and margin expansion, supported by strong product pipelines. However, tariffs are expected to have a $100 million cost-of-sales impact in 2025, with an incremental $50-$100 million headwind in 2026, creating near-term pressure.
Top Insights
Alcon launched TOTAL30 Multifocal for Astigmatism in the U.S. in February with early adoption likely to lift Vision Care sales and recurring revenue
Alcon's Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors
The company shows a free cash flow yield of 4.11% and debt to equity of 0.24, supporting balance-sheet resilience relative to peers in Healthcare
Alcon identified approximately $100 million of run-rate savings, with approximately $50 million expected to benefit 2026 and total program cost estimated at $150 million, with implementation expected to be completed in 2026
Named Competitors
Surgical eye care devices and equipment — Vision care products and ophthalmic devices
Cataract and refractive surgery systems — Ophthalmic diagnostic and surgical equipment
Contact lenses and ocular care — Vision care and contact lens portfolio
Refractive surgery platforms — Implantable collamer lenses (pending Alcon acquisition)
Recent Developments
(February 2026) Launched TOTAL30 Multifocal for Astigmatism in U.S. market
(February 2026) Reported Q4 2025 results with 7% full-year sales growth to $10.3B and announced 2026 guidance of 5-7% sales growth
(January 2026) Completed $750 million share repurchase program and returned $848 million to shareholders in 2025
Open the full interactive Alcon Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.